Companies

IS Pharma

Overview

IS Pharma was formed when Aim-quoted Maelor acquired Speciality European Pharma International for an initial £9.25m, with the possibility of its increasing to £14.25m over a five year period. SEP's main product is Haemopressin, which is used to treat uncontrolled bleeding from oesophageal varices. The company also supplies a range of hospital medicines aimed at niche markets which are of little interest to the major pharmaceutical companies. IS Pharma (Maelor) joined Aim on 21 November 1997 via a placing at 88p a share - equivalent to 616p post-consolidation. On 22 April 2008 seven shares were consolidated into one new share.

Sector: Health

News blog

• IS Pharma Posted: 10/10/2010
• IS Pharma Posted: 27/07/2010
• IS Pharma Posted: 02/06/2010
• IS Pharma Posted: 20/04/2010
• IS Pharma Posted: 22/03/2010
• IS Pharma Posted: 11/01/2010
• IS Pharma Posted: 22/06/2009
• IS Pharma Posted: 03/06/2009
• IS Pharma Posted: 05/11/2008
• IS Pharma Posted: 03/09/2008
• IS Pharma Posted: 25/04/2008
• Maelor Posted: 11/02/2008
• Maelor Posted: 08/11/2007

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period